The Society of Thoracic Surgeons and European Association for Cardio-Thoracic Surgery say more information is still required before any conclusions can be made about the long-term benefits of TAVR in low-risk patients.

The mitral valve has been an especially challenging target for transcatheter interventions, but there are reasons to think key breakthroughs are on the horizon. We talked to Kendra Grubb, MD, about this and other ongoing trends at TCT 2023. 

The new-look algorithm, trained and validated with data from more than 25,000 patients, scans a patient's electronic health record and identifies signs of trouble. 

The drug, nimodipine, is a second-generation calcium channel blocker designed to prevent and treat cerebral vasospasm following an aneurysmal subarachnoid hemorrhage.

Kendra Grubb, MD, one of the country's leading experts on cardiac surgery, discussed what she tells her patients when they ask if TAVR is better than SAVR for treating severe aortic stenosis. 

More than 100 U.S. medical societies are throwing their support behind a new proposal that could reform out-of-date Medicare policies and help limit future payment cuts. 

Implanting the Barostim device is now associated with an average payment amount of $45,000, up significantly from the previous average of $29,000.

All eyes were on TAVR during the first round of late-breaking clinical trials at TCT 2023 in San Francisco. Researchers shared key updates related to devices from Edwards Lifesciences, Medtronic, Boston Scientific and JenaValve Technology.

The Aurora EV-ICD MRI SureScan is similar in size and shape to traditional ICDs, but it is implanted outside of the patient’s heart and veins.

The AHA is suing HHS over guidance that forbids the use of popular third-party tracking applications.

“Developing personalized surveillance programs can be beneficial for these women,” researchers detailed recently in JAMA Oncology.